On the contrary, PD-L1 is generally high in EGFR-mutated NSCLC, but immunotherapy appeared to be less effective in this subgroup of patients, and treatment is often burdened by serious side effects (Table 1 and Table 2); [12,13,14,15,16,17,18,19,20,21,22,23]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.